Biologic medications have changed how rheumatologists treat autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. These treatments can help control inflammation, reduce joint damage, and improve patients’ quality of life. However, providing biologic therapy involves more than selecting the right medication. Rheumatology practices must also understand how these expensive drugs are purchased, covered by insurance, and reimbursed.
Two major approaches influence this process: buy-and-bill and specialty pharmacy. Although both allow patients to receive biologic treatment, they create different financial responsibilities, billing procedures, and administrative challenges. Understanding these differences is essential for practices that want to protect revenue while maintaining reliable patient access to treatment.
Understanding The Buy-And-Bill Reimbursement Model
In the buy-and-bill model, a rheumatology practice purchases biologic medications from an authorized distributor before administering them to patients. The practice maintains the inventory, provides the treatment, and submits an insurance claim for the medication and associated administration services.
This arrangement gives providers greater control over medication availability and treatment scheduling. However, it also means that the practice must spend money before receiving payment from the insurance company.
Consider a practice purchasing an expensive biologic medication for an upcoming infusion appointment. The medication must be paid for even though reimbursement may take several weeks. If the insurance company subsequently denies the claim because of incorrect coding or missing authorization, the practice faces a financial problem.
Under Medicare Part B, many separately payable physician-administered drugs are reimbursed using the Average Sales Price (ASP) methodology, commonly ASP plus 6%, subject to applicable payment adjustments. Commercial insurance companies may use different contracted rates.
Therefore, successful buy-and-bill management requires careful purchasing decisions, accurate billing, and continuous monitoring of reimbursement.
How Specialty Pharmacy Reimbursement Works
The specialty pharmacy model follows a different approach. Instead of purchasing the medication directly, the rheumatology practice coordinates with a specialty pharmacy that obtains and supplies the prescribed biologic.
In a common arrangement known as white bagging, the pharmacy delivers a patient-specific medication directly to the healthcare facility. The rheumatology practice administers the medication, while the specialty pharmacy generally bills the patient’s pharmacy benefit for the drug.
The practice typically submits a separate claim for the administration service.
This arrangement reduces the need for practices to invest large amounts of money in biologic inventory. It can also transfer certain medication distribution responsibilities to the specialty pharmacy.
However, it introduces additional coordination requirements. The practice must confirm insurance approval, prescription processing, medication delivery, and treatment scheduling. A shipment delay or pharmacy processing problem can disrupt an otherwise appropriate treatment plan.
Another arrangement, called brown bagging, involves shipping medication directly to the patient, who brings it to the healthcare facility. This creates additional concerns about proper storage, transportation, and medication handling.
Financial Differences Between Buy-And-Bill And Specialty Pharmacy
The biggest difference between these models is how financial responsibility is distributed.
With buy-and-bill, the practice carries the initial medication expense and waits for reimbursement. This can create cash flow pressure, particularly for smaller rheumatology clinics treating multiple patients with high-cost biologics.
Specialty pharmacy arrangements generally reduce this upfront purchasing burden because the pharmacy supplies and bills for the medication. However, practices should evaluate whether their administration reimbursement adequately covers staffing, infusion equipment, facility expenses, and other treatment-related costs.
For example, a practice administering several biologic infusions each week may generate medication-related revenue under an appropriate buy-and-bill arrangement. Under specialty pharmacy, that drug reimbursement generally goes to the pharmacy instead. The practice must therefore understand the financial impact on its overall revenue.
Neither model guarantees better profitability. Actual results depend on acquisition costs, payer contracts, reimbursement rates, operational expenses, and the number of treatments provided.
Key Reimbursement Challenges For Rheumatology Practices
Regardless of the medication distribution model, several operational issues can affect reimbursement.
1. Prior Authorization Requirements
Insurance companies may require documentation of medical necessity, previous treatment attempts, diagnosis, and prescribed dosage before approving biologic therapy. An expired authorization or missing clinical information can delay treatment and lead to claim denials.
2. Medication Coding And Billing Accuracy
Buy-and-bill claims require accurate HCPCS coding, including the appropriate drug code and billing units. Incorrect dosage calculations or code selection can result in underpayments, rejections, or compliance concerns.
3. Coordination Between Multiple Parties
Specialty pharmacy arrangements involve communication between the provider, insurer, pharmacy, and patient. Unclear responsibilities can lead to duplicate authorization requests, delayed shipments, and missed appointments.
4. Medication Documentation
Practices must maintain accurate records of the medication administered, dosage, date of service, and relevant administration details. Proper documentation supports accurate claims and provides evidence when responding to payer questions.
5. Denial And Underpayment Management
A submitted claim does not guarantee full reimbursement. Practices should regularly investigate unpaid claims, compare payments against contracted rates, and appeal incorrect denials within payer deadlines.
How Rheumatology Practices Can Choose The Right Model
Selecting a reimbursement model should begin with an evaluation of the practice’s financial position and operational capabilities.
Practices with sufficient working capital, reliable inventory management, and experienced billing teams may find buy-and-bill suitable for certain physician-administered biologics.
On the other hand, practices looking to reduce medication purchasing responsibilities may consider specialty pharmacy arrangements where permitted by their payer contracts and applicable policies.
The decision should also account for patient access. Medication availability, insurance requirements, treatment urgency, and reliable delivery are important considerations. A financially attractive arrangement is not necessarily the best option if it repeatedly interrupts patient treatment.
Importantly, practices should verify payer-specific rules before selecting a model because some insurers restrict medication sourcing or require particular distribution arrangements.
How Kaizen Systems Supports Better Biologic Reimbursement
Managing biologic reimbursement requires coordination across multiple stages of the revenue cycle. A problem during authorization, coding, claim submission, or payment posting can affect the financial performance of an entire treatment program.
Kaizen Systems helps healthcare practices strengthen these processes through medical billing, coding support, prior authorization management, and denial management.
For rheumatology practices, effective revenue cycle management means identifying reimbursement problems early, maintaining accurate documentation, reviewing outstanding claims, and following up on payment discrepancies.
Rather than treating each denied claim as an isolated problem, practices can benefit from identifying recurring patterns and improving the underlying billing workflow.
Conclusion
Buy-and-bill and specialty pharmacy are two different approaches to managing biologic medication reimbursement in rheumatology. Both require effective rheumatology medical billing to ensure accurate claims, proper reimbursement, and efficient revenue cycle management. Buy-and-bill provides greater control over medication purchasing and inventory but exposes practices to upfront costs and reimbursement risks. Specialty pharmacy reduces direct inventory investment but requires stronger coordination between pharmacies, insurers, providers, and patients.
The right approach depends on payer policies, financial resources, operational capacity, and patient needs. Regardless of the model, accurate coding, authorization management, complete documentation, and consistent claims follow-up remain essential.
With a well-managed reimbursement process and the right billing support, rheumatology practices can improve financial visibility, reduce avoidable payment delays, and focus more effectively on delivering quality patient care.
